Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities research analysts at Leerink Swann increased their Q3 2017 earnings estimates for Neurocrine Biosciences in a research note issued on Tuesday. Leerink Swann analyst P. Matteis now forecasts that the company will post earnings per share of ($0.50) for the quarter, up from their previous estimate of ($0.51). Leerink Swann currently has a “Outperform” rating and a $72.00 price objective on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at ($0.40) EPS, FY2017 earnings at ($2.48) EPS and FY2018 earnings at ($2.10) EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.01). The company had revenue of $6.34 million for the quarter, compared to analyst estimates of $0.61 million. During the same period last year, the company posted ($0.46) EPS.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/12/q3-2017-earnings-estimate-for-neurocrine-biosciences-inc-issued-by-leerink-swann-nbix.html.

A number of other brokerages also recently weighed in on NBIX. BMO Capital Markets reaffirmed an “outperform” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 7th. ValuEngine raised shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 21st. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $68.81.

Neurocrine Biosciences (NASDAQ NBIX) opened at 61.86 on Thursday. Neurocrine Biosciences has a 52-week low of $37.35 and a 52-week high of $63.77. The firm’s market capitalization is $5.46 billion. The company’s 50-day moving average is $58.03 and its 200-day moving average is $51.01.

Institutional investors and hedge funds have recently bought and sold shares of the company. Canada Pension Plan Investment Board raised its position in shares of Neurocrine Biosciences by 49.7% in the 2nd quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock worth $1,136,000 after purchasing an additional 8,200 shares during the last quarter. BlackRock Inc. raised its position in shares of Neurocrine Biosciences by 14,216.0% in the 1st quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock worth $217,884,000 after purchasing an additional 4,996,784 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Neurocrine Biosciences in the 1st quarter worth about $4,330,000. Schwab Charles Investment Management Inc. raised its position in shares of Neurocrine Biosciences by 8.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 346,906 shares of the company’s stock worth $15,022,000 after purchasing an additional 27,245 shares during the last quarter. Finally, Janus Capital Management LLC raised its position in shares of Neurocrine Biosciences by 85.0% in the 1st quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock worth $188,759,000 after purchasing an additional 2,002,899 shares during the last quarter.

In other news, insider Haig P. Bozigian sold 26,250 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the sale, the insider now owns 144,601 shares in the company, valued at approximately $8,676,060. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $50.00, for a total transaction of $436,700.00. Following the sale, the insider now owns 57,707 shares in the company, valued at approximately $2,885,350. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 132,580 shares of company stock worth $7,440,850. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.